The first FDA-approved clinical trial of psilocin has begun

Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder

Filament Health Announces Transition From OTCQB To OTC Pink Limited

Filament Health Announces Voluntary Delisting From Cboe Canada